Replies to post #12501 on Humanigen Inc (HGENQ)

[Engineering_Simple]

like MWM mentioned yesterday, NIH study was material news so they had to disclose it.

That's why it was the header of the 8-K filed yesterday.
https://www.sec.gov/Archives/edgar/data/1293310/000121465920006613/h7272028k.htm

Per SEC:

"Form 8-K provides investors with current information
to enable them to make informed decisions. The
types of information required to be disclosed on
Form 8-K are generally considered to be “material.”
That means that, in general, there is a substantial
likelihood that a reasonable investor would consider
the information important in making an investment
decision. "

https://www.sec.gov/investor/pubs/readan8k.pdf

[rstar]

company is required to disclose material events as they happen.
worth reading through full clinical trial agreement filed after the pr:
https://www.sec.gov/Archives/edgar/data/1293310/000121465920006613/ex10_1.htm

$HGEN!

[PITrader87]

I'm with you in questioning why there have been no other sources for this information. I don't understand the timing of the PR unless it was needed to put in an 8-k for clerical reasons with the uplist to the NASDAQ.

There is a reason the NIAID has not specifically stated the drug name of the monoclonal antibody they are testing, I'm just speculating as to why that would be. What we do know is that the head of the NIAID just stated that a trial of a monoclonal antibody was initiated this week & HGEN announced they were selected for a trail with the NIAID this week.

[dloggold]

Are we up to twenty shareholders? Nice